AMD Invests $20M in Absci to Expand AI in Healthcare
AMD is investing $20 million in drug-discovery company Absci, marking its entry into healthcare AI.
The partnership aims to optimize AI solutions, lower hardware costs, and increase AMD’s GPU usage at Absci.
AMD targets healthcare as a key vertical, competing with Nvidia, which invested $50M in Recursion Pharmaceuticals.
Absci will shift some AI workloads from Nvidia GPUs to AMD’s, addressing rising computational costs in drug discovery.
Absci will use the funding to enhance AI models, drug development, and clinical trials targeting inflammatory bowel disease.
